Abstract：
OBJECTIVE: The recent consensus statement of ESPEN and EASO recommends reviewing existing datasets to assess the prevalence of sarcopenic obesity based on the new definition and diagnostic criteria. Therefore, this study aimed to determine the prevalence of sarcopenic obesity in a population-based study and to assess the association of this new definition with clinical traits.
METHODS: The KORA (Cooperative Health Research in the Region of Augsburg)-Age baseline examination (2008/2009) comprised 1079 participants aged 65 years and older from southern Germany. Sarcopenic obesity was defined in 998 participants (mean age 75.6 years, 498 women) with complete data according to the 2022 ESPEN and EASO algorithm, which includes reduced handgrip strength, reduced skeletal muscle mass per weight, and elevated fat mass. Body composition was measured using bioelectrical impedance analysis. Associations between sarcopenic obesity and physical activity, disability, multimorbidity, and polypharmacy were assessed using logistic regression analysis.
RESULTS: The overall prevalence of sarcopenic obesity was 4.5 % (5.0 % in men, 4.0 % in women). Sarcopenic obesity was associated with disability (2.87 [CI 1.84-4.48]), multimorbidity (≥ 2 comorbidities; 2.59 [CI 1.23-5.46]), polypharmacy (≥ 5 drugs; 1.96 [CI 1.05-3.63]), cognitive impairment (3.03 [CI 1.51-6.06]) and arthritis (2.66 [CI 1.39-5.07]) after adjusting for age, sex and marital status.
CONCLUSIONS: Sarcopenic obesity is prevalent in the older German population and is associated with several clinical traits. Future longitudinal studies are needed to further elucidate whether the observed associations could be causal.
METHODS: The KORA (Cooperative Health Research in the Region of Augsburg)-Age baseline examination (2008/2009) comprised 1079 participants aged 65 years and older from southern Germany. Sarcopenic obesity was defined in 998 participants (mean age 75.6 years, 498 women) with complete data according to the 2022 ESPEN and EASO algorithm, which includes reduced handgrip strength, reduced skeletal muscle mass per weight, and elevated fat mass. Body composition was measured using bioelectrical impedance analysis. Associations between sarcopenic obesity and physical activity, disability, multimorbidity, and polypharmacy were assessed using logistic regression analysis.
RESULTS: The overall prevalence of sarcopenic obesity was 4.5 % (5.0 % in men, 4.0 % in women). Sarcopenic obesity was associated with disability (2.87 [CI 1.84-4.48]), multimorbidity (≥ 2 comorbidities; 2.59 [CI 1.23-5.46]), polypharmacy (≥ 5 drugs; 1.96 [CI 1.05-3.63]), cognitive impairment (3.03 [CI 1.51-6.06]) and arthritis (2.66 [CI 1.39-5.07]) after adjusting for age, sex and marital status.
CONCLUSIONS: Sarcopenic obesity is prevalent in the older German population and is associated with several clinical traits. Future longitudinal studies are needed to further elucidate whether the observed associations could be causal.
摘要：
目的：ESPEN和EASO最近的共识声明建议回顾现有的数据集，根据新的定义和诊断标准评估少节性肥胖的患病率。因此,本研究旨在确定一项基于人群的研究中节育性肥胖的患病率,并评估这一新定义与临床特征的相关性.
方法：KORA（奥格斯堡地区合作健康研究）-年龄基线检查（2008/2009）包括来自德国南部的1079名65岁及以上的参与者。在998名参与者中定义了肌肉减少性肥胖(平均年龄75.6岁，498名女性）根据2022年ESPEN和EASO算法具有完整的数据，其中包括降低的握力，减少单位重量的骨骼肌质量，和增加的脂肪量。使用生物电阻抗分析测量身体成分。肌少症肥胖和体力活动之间的关联，残疾,多浊度,和多重用药采用logistic回归分析进行评估。
结果：减少肌性肥胖的总体患病率为4.5％（男性为5.0％，4.0%的女性)。肌肉减少性肥胖与残疾相关（2.87[CI1.84-4.48]），多发病率（≥2合并症；2.59[CI1.23-5.46]），多重用药（≥5种药物；1.96[CI1.05-3.63]），调整年龄后的认知障碍（3.03[CI1.51-6.06]）和关节炎（2.66[CI1.39-5.07]），性别和婚姻状况。
结论：肌肉节制性肥胖在德国老年人群中普遍存在，并与一些临床特征相关。未来的纵向研究需要进一步阐明观察到的关联是否可能是因果关系。
方法：KORA（奥格斯堡地区合作健康研究）-年龄基线检查（2008/2009）包括来自德国南部的1079名65岁及以上的参与者。在998名参与者中定义了肌肉减少性肥胖(平均年龄75.6岁，498名女性）根据2022年ESPEN和EASO算法具有完整的数据，其中包括降低的握力，减少单位重量的骨骼肌质量，和增加的脂肪量。使用生物电阻抗分析测量身体成分。肌少症肥胖和体力活动之间的关联，残疾,多浊度,和多重用药采用logistic回归分析进行评估。
结果：减少肌性肥胖的总体患病率为4.5％（男性为5.0％，4.0%的女性)。肌肉减少性肥胖与残疾相关（2.87[CI1.84-4.48]），多发病率（≥2合并症；2.59[CI1.23-5.46]），多重用药（≥5种药物；1.96[CI1.05-3.63]），调整年龄后的认知障碍（3.03[CI1.51-6.06]）和关节炎（2.66[CI1.39-5.07]），性别和婚姻状况。
结论：肌肉节制性肥胖在德国老年人群中普遍存在，并与一些临床特征相关。未来的纵向研究需要进一步阐明观察到的关联是否可能是因果关系。
